ALS Association – The Hoffman ALS Clinical Trial Awards Program
Expire le 18 novembre 2025
Description: These grants support early- to mid-stage (phase 1 or 2a) biomarker-driven clinical trials of novel or repurposed therapeutics for ALS (either disease-modifying or symptomatic) or of imaging tracers.
Funding: Up to $1,000,000 over 2 or 3 years
LOI Deadline (extended): November 18, 2025, 1 p.m. U.S. ET
Full Proposal Due (by invitation only): February 17, 2026, 1 p.m. U.S. ET